Delivering confidence in MRD testing

Superb ctDNA detection accuracy

We empower clinicians and biopharma with exceptionally accurate insights that help inform clinical management and therapeutic development.

For clinicians

For biopharma

High precision

Exceptional sensitivity and specificity

Based on technology built by pioneers of cancer genomics and further developed by Quest Diagnostics, Haystack MRD^® is an advanced tumor-informed minimal residual disease (MRD) test that detects circulating tumor DNA (ctDNA) in blood using proprietary technology that checks both DNA strands for each variant. This method results in superb accuracy for more precise, informed clinical choices across diverse clinical applications.

Neoadjuvant response

Measure ctDNA in the neoadjuvant setting to assess treatment response.

Residual disease detection

Exceptional sensitivity and specificity for informed adjuvant therapy decision-making.

Treatment response assessment

Follow patient’s response to adjuvant therapy to greater depths and with better sensitivity than traditional methods.

Recurrence surveillance

Limit of detection of 0.0006% means that patients who recur may be identified earlier than with traditional methods.

Purpose-built

The Haystack MRD difference

MRD testing demands highly accurate ctDNA detection. Haystack MRD is a tumor-informed, next-generation MRD test that detects ultralow levels of ctDNA to uncover residual disease after definitive surgery.

A track record of Innovation and leadership

Haystack MRD is the product of more than 20 years of pioneering work in liquid biopsy technologies and further development by Quest Diagnostics.

Haystack technology was built on the foundational work of cancer genomics pioneers, whose discoveries have transformed clinical practice for cancer patients.

Haystack technology Doubles down on confidence

Through patented error-correction technology, Haystack MRD performs deep sequencing to confirm that variants are detected on both DNA strands, effectively double-checking each variant. By setting a higher standard for accuracy, Haystack MRD provides results clinicians can act on with confidence.

See the data

Prioritized patient access with The power of Quest

Haystack MRD is part of Quest Diagnostics—one of the world’s leading provider of diagnostic services. With Quest’s proven ability to scale innovation from the lab bench to millions of patients, Haystack MRD is part of one of the broadest test solution portfolios in oncology and beyond.

questdiagnostics.com

Industry upates

Recent news

Find out what’s happening with Haystack oncology solutions and stay up-to-date with industry news.

Webinar: How ctDNA can assist in critical nonoperative management decisions

November 14, 2025

Oncologists like Dr Doug Flora and Dr Debra Patt are realists. But when they began to use new tools to find cancer that surgery or treatment might have missed, something exciting happened.

We’ll be at ESMO 2025

October 14, 2025

Join us at the 2025 European Society for Medical Oncology (ESMO) Congress as we share how Haystack MRD, our tumor-informed ctDNA test, is helping redefine the role of minimal residual disease testing in clinical practice and oncology drug development.

Haystack Oncology and Rutgers Cancer Institute Collaborate in a Clinical Study to Examine Haystack MRD as a Guide for Post-Surgical Treatment for Lung Cancer

September 22, 2025

Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, today announced a research collaboration with the Rutgers Cancer Institute to evaluate the use of Haystack MRD®, a highly sensitive circulating tumor DNA (ctDNA) minimal residual disease (MRD) test, to help optimize postoperative therapy decisions in patients with stage II/III non-small cell lung cancer (NSCLC). Rutgers Cancer Institute together with RWJBarnabas Health is the state's only National Cancer Institute-designated Comprehensive Cancer Center.

All news